IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia

IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML), BCR-ABL1-positive, is classified as a myeloproliferative characterized by Philadelphia chromosome/translocation t(9;22) and proliferating granulocytes. Despite the clinical success of tyrosine kinase inhibitors (TKi) agents in the treatment of CML, most patients have...

Full description

Bibliographic Details
Main Authors: Daniela Cambria, Lucia Longhitano, Enrico La Spina, Sebastiano Giallongo, Laura Orlando, Rosario Giuffrida, Daniele Tibullo, Paolo Fontana, Ignazio Barbagallo, Vincenzo Giuseppe Nicoletti, Giovanni Li Volti, Vittorio Del Fabro, Anna Rita Daniela Coda, Arcangelo Liso, Giuseppe Alberto Palumbo
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Life
Subjects:
chronic myeloid leukemia
dasatinib
IGFBP6
TLR4
mesenchymal stromal cells
Online Access:https://www.mdpi.com/2075-1729/13/2/259

Internet

https://www.mdpi.com/2075-1729/13/2/259

Similar Items